FDA Accepts IND for Poseida Therapeutics’ Allogeneic CAR-T Cell Therapy Candidate

News
Article

FDA has cleared an IND from Poseida Therapeutics, allowing continued development of the company’s allogeneic CAR-T cell therapy candidate for treating multiple solid tumors.

Poseida Therapeutics, a US-based clinical-stage biopharmaceutical company specializing in cell and gene therapeutics using its proprietary genetic engineering platform technologies, received clearance in December 2021 by FDA for its investigational new drug (IND) application for P-MUC1C-ALLO1, an allogeneic chimeric antigen T cell (CAR-T) product candidate which the company is developing to treat multiple solid tumors.

The IND clearance for P-MUC1C-ALLO1 follows an IND clearance the company received for its P-BCMA-ALLO1, another allogeneic CAR-T therapy candidate in development for treating relapsed/refractory multiple myeloma. P-MUC1C-ALLO1 is the first product candidate to be produced out of the company’s new good manufacturing practice facility—an internal pilot manufacturing plant—at its San Diego, Calif., headquarters.

P-MUC1C-ALLO1 will be evaluated in a Phase I study in adults with locally advanced or metastatic epithelial-derived solid tumors refractory to standard of care therapy, or those deemed ineligible or who have been refused another existing treatment option. The study will evaluate the safety, tolerability, and preliminary efficacy of the product candidate.

“We are excited to begin the P-MUC1C-ALLO1 trial, an evaluation of a fully allogeneic CAR-T product candidate with the potential to treat a wide range of solid tumors, including breast, ovarian, and other cancers,” said Eric Ostertag, CEO of Poseida Therapeutics, in a Dec. 20, 2021 company press release. “The genetic edits in P-MUC1C-ALLO1 have been shown to reduce or fully eliminate alloreactivity, and our proprietary manufacturing process, which includes our booster molecule, has the potential to treat many patients from a single manufacturing run. We look forward to beginning this trial and to presenting initial clinical data in 2022.”

Source: Poseida Therapeutics

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes